Amphastar Pharmaceuticals (AMPH) Receivables (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Receivables of $147.8 million for Q1 2026, up 2.22% year-over-year from $144.6 million in Q1 2025, and up 2.99% quarter-over-quarter from $143.6 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Receivables (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Receivables history runs 14 years deep, the most recent figure standing at $147.8 million for Q1 2026.
- In Q1 2026, Receivables rose 2.22% year-over-year to $147.8 million; the TTM figure through Mar 2026 stood at $147.8 million (up 2.22% YoY), while the FY2025 annual figure was $143.6 million, up 5.33% from the prior year.
- Receivables for Q1 2026 stood at $147.8 million, up from $143.6 million in the prior quarter.
- The five-year high for Receivables was $147.8 million in Q1 2026, with the low at $73.2 million in Q1 2022.
- The 5-year median for Receivables is $131.7 million (2024), against an average of $119.0 million.
- The sharpest annual moves came in 2022 and 2023: Receivables declined 6.12% in 2022, then soared 53.93% in 2023.
- Amphastar Pharmaceuticals' Receivables stood at $88.8 million in 2022, then increased by 29.43% to $114.9 million in 2023, then increased by 18.57% to $136.3 million in 2024, then grew by 5.33% to $143.6 million in 2025, then advanced by 2.99% to $147.8 million in 2026.
- Business Quant data shows AMPH's Receivables at $147.8 million in Q1 2026, $143.6 million in Q4 2025, and $147.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.08 Bn |
| 10 | Amphastar Pharmaceuticals | 943.15 Mn | 653.02 Mn | 93.47 Mn | 145.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145.76 Mn |
| Mar 31, 2026 | 147.85 Mn |
| Dec 31, 2025 | 143.56 Mn |
| Sep 30, 2025 | 147.31 Mn |
| Jun 30, 2025 | 133.48 Mn |
| Mar 31, 2025 | 144.64 Mn |
| Dec 31, 2024 | 136.29 Mn |
| Sep 30, 2024 | 140.04 Mn |
| Jun 30, 2024 | 131.71 Mn |
| Mar 31, 2024 | 138.41 Mn |
| Dec 31, 2023 | 114.94 Mn |
| Sep 30, 2023 | 118.99 Mn |
| Jun 30, 2023 | 104.72 Mn |
| Mar 31, 2023 | 100.84 Mn |
| Dec 31, 2022 | 88.80 Mn |
| Sep 30, 2022 | 77.30 Mn |
| Jun 30, 2022 | 80.81 Mn |
| Mar 31, 2022 | 73.17 Mn |
| Dec 31, 2021 | 78.80 Mn |
| Sep 30, 2021 | 78.09 Mn |